Amanta Healthcare logo

Amanta Healthcare financials: balance sheet, profit and loss, cash flow

NSE: AMANTABSE: 544502Pharmaceuticals & BiotechnologySmall Cap

Amanta Healthcare Limited · Face value ₹10 · Listed Sep 2025 · Issue price ₹126
Last close ₹163.56down ₹7.34 (4.29%)BSE ₹162.75

Share price at the NSE close on 30 Oct 2026. Previous close ₹170.90.

30 Oct: open ₹169.19, high ₹171.19, low ₹161.22

52-week range of traded prices to 30 Oct 2026
₹92.00Low, 16 Mar 2026₹209.95High, 10 Sep 2026
Market cap
₹635 Cr1,889th largest listed
P/E
43.27
P/E without one-offs
36.70
P/B
2.88
Dividend yield
Nonein the last 12 months
ROE
6.7%
ROE without one-offs
7.9%
ROCE
9.0%
Debt to equity
1.06
Volume, NSE
53,58651.2% delivered

Amanta Healthcare's financial statements for the year to Mar 2026, standalone: the listed company alone, without its subsidiaries, with the twelve months to Jun 2026 after them.

1 year at a glance

₹ crore, years to March.Amanta Healthcare annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
28815234Mar 26

Operating and net margin, per cent

  • Operating margin
  • Net margin
20.8%5.2%20.8%5.2%Mar 26

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue288
  2. Materials and goods−97
  3. Employee costs−43
  4. Other expenses−88
  5. Operating profit60
  6. Depreciation−19
  7. Other income+3.4
  8. One-off items−2.6
  9. Finance costs−21
  10. Profit before tax21
  11. Tax−6.2
  12. Net profit15

What the company owns

  • Plant, investments and other assets₹340 Cr
  • Cash and bank₹93 Cr
  • Inventory₹83 Cr
  • Receivables₹43 Cr

What pays for it: net worth and liabilities

  • Borrowings₹234 Cr
  • Net worth₹220 Cr
  • Other liabilities₹67 Cr
  • Owed to suppliers₹36 Cr

Profit and loss

Standalone, ₹ crore, years to March. The last column is the twelve months to Jun 2026, the latest four quarters added.Amanta Healthcare quarterly results

₹ croreMar 2026Jun 2026Twelve months
Revenue from operations288291
228232
Materials and goods bought9799
Employee costs4344
Other expenses8888
Operating profit before depreciation6060
Operating margin20.8%20.4%
Materials, % of revenue33.6%34.1%
Employee costs, % of revenue14.9%15.2%
Other expenses, % of revenue30.7%30.3%
Depreciation and amortisation1919
Operating profit after depreciation4141
Other income33
Finance costs2120
Profit before one-off items and tax2423
One-off items−3−3
Profit before tax2121
66
Net profit1515
Other comprehensive income−1−1
Total comprehensive income1414
Net margin5.2%5.0%

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2026
220
Share capital39
Reserves181
234
141
197
Total assets558
320
238
Net debt142
Borrowings are counted again inside the liabilities due within a year and after a year.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2026
48
56
−6
Receivables7
Inventories−10
Payables5
Other working capital−8
Tax paid−7
Capital spending80
Free cash flow−32
−94
126
Dividends paid0
Shares bought back0
Shares issued126
Net change in cash81
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only.

Per share

Standalone, ₹ per share, years to March.

₹ per shareMar 2026
Earnings per share₹4.33
Diluted earnings per share₹4.33
Book value per share₹56.71
Shareholder yield−32.4%
Market cap at the year end (₹ crore)388

Ratios

Standalone, years to March.Amanta Healthcare PE ratio and valuation

RatioMar 2026
Return on equity6.8%
Return on capital employed9.0%
Cash conversion325.7%
Interest cover2.0
Debt to equity1.06
Receivable days55
Inventory days312
Payable days136
Cash conversion cycle, days231
Working capital days97
Asset turnover0.52
Assets per rupee of net worth2.53
Sales per rupee of plant1.46
Capital spending to depreciation4.28
Plant being built, % of plant in use41.8%

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
2.7%
Cash from operations against operating profit
80.9%

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ croreLatest year
Cash from operations48
Cash from investing−94
Cash from financing126
Capital spending80
Dividends paid0
Shares bought back0
Shares issued for cash126
Borrowings raised79
Borrowings repaid41

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2026
Altman Z-scorePublished threshold 1.812.11
Effective tax ratePublished threshold 17.16 per cent29.58
Tax charged less tax paid, % of profitOur threshold 10 percentage points−3.82
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBRating upgradedStable18.70
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBRating upgradedStable2.40
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBRating upgradedStable115
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBRating upgradedStable6.28
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBRating upgradedStable50
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesLong-term scaleCrisil BBBRating upgradedStable3.62
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesCrisil BBBReview, UpgradeStable38.25
16 Feb 2026CRISIL Ratings LimitedBank FacilitiesCrisil A3+Review, Upgrade10.75
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.